Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

FDA greenlights new COVID-19 booster despite limited data - Roll Call

The Food and Drug Administration granted emergency authorization to Pfizer and Moderna for updated COVID-19 booster shots.

Roll Call

What Are Whales Doing With Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

COVID-19 vaccine now available for at-risk children under five as new cases remain low

Young children with complex health conditions are now eligible for COVID vaccinations.

The Canberra Times

From analysis to the latest developments in health,
read the most diverse news in one place.

This Is What Whales Are Betting On Pfizer

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 29 strange trades.

Benzinga

Should you get a Covid-19 booster now, or wait until the fall?

As we gear up for another wave of Covid-19 this fall, experts say you should definitely be prepared to get a booster shot. Here's when you should get it.

Inverse

Moderna's COVID vaccine lawsuit looks ahead to future markets

Moderna's COVID vaccine lawsuit looks beyond the pandemic to future markets

Axios

Omicron COVID-19 booster shots are coming: What you need to know

The next generation of COVID-19 booster shots — tailored specifically to combat the highly infectious family of omicron subvariants — could roll out early next month.

Los Angeles Times

Read news from The Economist, FT, and more,
with one subscription

Q&A: The new COVID vaccine booster is coming. Should you get it?

The COVID-19 vaccine is getting an upgrade.

Tribune News Service

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga

Moderna Sues Pfizer/BioNTech for Patent Infringement over COVID Vaccine

Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%…

Asharq Al-Awsat

Biden team aims for omicron-targeted shots in arms by Labor Day

The Biden administration plans to begin offering next-generation COVID-19 booster shots as soon as the Labor Day weekend, according to people familiar with the matter, aiming to stave off a fall surge in cases of the disease.

Tribune News Service

US Covid vaccine maker Moderna suing rivals Pfizer and BioNTech over jab

The company said it believes its rivals’ vaccine infringes on patents Moderna filed between 2010 and 2016

Wales Online

Pfizer asks EU drug regulator to OK tweaked COVID vaccine

Pharmaceuticals Pfizer and BioNTech say they have asked the European Medicines Agency to authorize their updated coronavirus booster vaccine that includes the most recent omicron subvariants

The Independent UK

Moderna sues Pfizer over COVID-19 vaccine patents

The vaccine maker alleges that its rivals Pfizer and BioNTech used some patented features of its mRNA technology to develop their COVID vaccines.

WEKU

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Moderna sues Pfizer and BioNTech over Covid-19 vaccine

The vaccine maker said it had filed patent infringement lawsuits in the US and Germany.

Evening Standard

Moderna sues Pfizer/BioNTech alleging patent infringement over Covid vaccine

Moderna seeks unspecified damages in lawsuit over rivals’ jab

Evening Standard

Covid infections at lowest level in two months- ONS

High levels of coronavirus antibodies among the population means the rate of serious illness remains low

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

Get all your
news in one place.

100's of premium titles.
One news app.

Bangkok Post

Thonburi Healthcare chairman resigns after market ban

Dr Boon Vanasin, the founder and chairman of Thonburi Healthcare Group (THG), is resigning from the company’s board as he faces a market ban in connection with claims he made last year about the purchase of Pfizer coronavirus vaccines.

Tribune News Service

Moderna sues Pfizer, BioNTech over COVID vaccine technology

Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.

Bangkok Post

Moderna sues Pfizer over Covid vaccine

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first Covid-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

The Independent UK

Moderna sues Pfizer over patents behind COVID-19 vaccine

COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine

The Independent UK

Moderna sues Pfizer-BioNTech accusing them of copying Covid shot technology

‘We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,’ Moderna legal officer says

StockNews.com

Is Pfizer a Buy Before New Omicron Boosters Roll Out?

Pharmaceutical giant Pfizer’s (PFE) omicron-targeted booster doses could soon be authorized this fall. The company has benefited largely from the pandemic and its vaccine rollouts. Now let’s find out if PFE is a Buy now as it prepares to roll out its booster doses….

Axios

Moderna sues Pfizer, BioNTech over COVID-19 vaccine

The lawsuit seeks unspecified monetary damages for patent infringement.

1 … 40 41 42 43

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

347 stories

PFE

346 stories

Centers for Disease Control and Prevention

European Medicines Agency

76 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.